	Pre-congress content	;			
Session title	Summary	Session type	Patient role	Disease areas	Link
ERS technical standards for scoring respiratory events using Type III devices for the diagnosis of sleep disordered breathing in adults and children	This session discusses the findings from a Task Force looking at devices to monitor sleep at home. These devices record breathing, oxygen levels and heart rate through the night to diagnose sleep disordered breathing. The session explains: • the advantages and disadvantages of these devices • what aspects need more research, and • how these devices compare to polysomnography, which is another way to monitor sleep.	Statements and technical standards	Patients were involved in developing the standards.	Sleep and breathing	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14491
ERS statement on long COVID-19 follow-up	This session outlines the findings from a Task Force looking at the care of people experiencing symptoms after a COVID-19 infection, often called long-COVID. The session: • examines whether there is a connection between how ill someone was with COVID-19 and the symptoms they experienced, and whether they develop long-COVID, and • explains how doctors can best provide care to people after a COVID-19 infection. This includes considering quality of life as well as physical symptoms.	Statements and technical standards		COVID-19	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14495
The ERS core outcome set for clinical trials evaluating the management of COPD exacerbations	A core outcome set is an agreed set of important health outcomes that should be measured in a clinical trial. Using a core outcome set can improve the quality of a trial and allow results to be compared between different trials. This session: describes the findings of a Task Force developing a core outcome set for exacerbations in COPD, which is a sudden worsening in symptoms, and	Statements and technical standards	Patients were involved in developing the core outcome set.	COPD	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14497





	explains how the Task Force included the outcomes most important to patients.				
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials	An exacerbation is a sudden worsening in symptoms. This session explains the findings of a Task Force developing a statement on how exacerbations in bronchiectasis should be measured in clinical trials with children and adolescents. The session will: • explain the impact and importance of exacerbations in children and young people with bronchiectasis, and • discuss how exacerbations should be categorised in a clinical trial, and how this is different to how they are defined in clinical care.	Statements and technical standards	Patients were involved in developing the statement.	Bronchiectasis	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14492
An ERS clinical research collaboration to advance research in alpha-1 antitrypsin deficiency	This session gives an update on the work of the clinical research collaboration EARCO. EARCO stands for European Alpha-1 Research Collaboration, and it promotes research and education in alpha-1 antitrypsin deficiency (AATD). EARCO is: • building a network of researchers and clinical experts in AATD to help decide on priorities for treatment and research, and • agreeing on the priorities for research from the perspectives of patients and doctors.	Clinical Research Collaboration	Patients are involved in the clinical research collaboration.	Alpha-1	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14499
Lessons learnt and updates from the CADSET clinical research collaboration	CADSET (Chronic Airway Diseases Early Stratification) is a clinical research collaboration promoting research into asthma and COPD. This session provides an update on the work of CADSET and what has been learned from it, including: • how early life may play a part in the development of chronic respiratory diseases • what factors influence lung function across a person's lifetime, and	Clinical Research Collaboration	Patients are involved in the clinical research collaboration.	Asthma COPD	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14502





Severe heterogenous asthma research collaboration,	the similarities and differences between asthma with fixed airflow limitation (where the person's lungs are narrowed permanently, not just during an asthma attack) and COPD. This session outlines the work of the clinical research collaboration SHARP (Severe Heterogenous Asthma Research collaboration, Patient-centred). SHARP aims to improve the understanding and treatment of	Clinical Research Collaboration	Patients are involved in the clinical research	Asthma	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio
patient-centred	severe asthma in a patient-centred way. This session will cover the following aspects: What SHARP aims to achieve Who is involved The key achievements so far How patients are involved Plans for the future How people can get involved in SHARP.		collaboration.		<u>n?e=377&session</u> =14504
EU-wide consensus of clinical experts and patients on key parameters to be measured during and after a severe exacerbation of COPD	This session discusses the outcomes of the clinical research collaboration CICERO (Collaboration in COPD Exacerbations). CICERO aims to improve understanding, treatment and outcomes for patients experiencing COPD exacerbations, which is a sudden worsening of symptoms. The session includes: • an outline of the results from a survey of patients with COPD and how these influenced the work of the project, and • an explanation of the importance of patient involvement in research collaborations.	Clinical Research Collaboration	Patients are involved in the clinical research collaboration.	COPD	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14505
Precision medicine for bronchiectasis	This session outlines the work of the clinical research collaboration EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration). EMBARC aims to promote research and education in bronchiectasis. This session looks at:	Clinical Research Collaboration	Patients are involved in the clinical research collaboration.	Bronchiectasis	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14521





	 how there are different symptoms and characteristics of bronchiectasis the latest research showing how bronchiectasis overlaps with COPD and asthma, and the latest research demonstrating that there are different types of inflammation in bronchiectasis and that these may need different treatments. 				
New understanding in the treatment of cough	This session provides an update on the work of the NEuroCOUGH (NEw Understanding in the tReatment Of COUGH) clinical research collaboration. NEuroCOUGH aims to improve the awareness, understanding and treatment of chronic cough. This session includes: NEuroCOUGH's work to advocate for chronic cough to be identified as a disease rather than a symptom the results of a survey of cough clinics the data NEuroCOUGH has collected on chronic cough, and how NEuroCOUGH has worked with the pharmaceutical industry to develop new treatments for chronic cough.	Clinical Research Collaboration	Patients are involved in the clinical research collaboration.	Chronic cough	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14522
Biologics in asthma: do we need so many and who do we miss?	Biological treatments can help stop inflammation in the lungs. This session looks at the latest research on the use of these treatments for asthma. It includes: • the link between the immune system and asthma • how biological treatments work • why biological treatments do not work well in some people, and • why it is important to analyse a patient's immune system before prescribing a biological treatment.	Year in Review		Asthma	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14645





Treatable traits in COPD rehabilitation	The 'treatable traits' model is a way of personalising treatment for chronic lung disease. It recognises that not all people with lung disease are the same. Treatable traits are characteristics associated with a lung condition that can include physical, emotional and social factors such as anxiety, smoking and how well someone is able to manage their illness. This session looks at how the treatable traits model can be used to personalise pulmonary rehabilitation for people with COPD.	Year in Review	COPD	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14646
Antibiotics in lower respiratory tract infections in children.	This session looks at the results of recent research into the use of antibiotics for lower respiratory tract infections and community acquired pneumonia (CAP) in children. It will consider, if antibiotics are needed, what is the best dose and how long they should be prescribed for.	Year in Review	Paediatric lung infections	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14651
What is new in tuberculosis: from prevention to treatment	This session looks at recent new research and development in tuberculosis. It covers: • diagnosis • new drugs and regimes • new biomarkers (such as genes and other biological characteristics), and • how artificial intelligence is being used in clinical trials.	Year in Review	Tuberculosis	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14887
Health effects of novel tobacco and nicotine products	This session outlines recent research into the health effects of electronic nicotine delivery systems (ENDS) and heated tobacco products (HTP), for example vaping. It then discusses whether regulations and policies relating to tobacco products need to change.	Year in Review	Nicotine and tobacco	https://k4.ersnet. org/prod/v2/Fron t/Program/Sessio n?e=377&session =14892





Treatment of T1 lung	T1 or stage 1 lung cancer is when the cancer is diagnosed early on and	Year in Review	Lung cancer	https://k4.ersnet.
cancer: novel	has not spread outside the lungs. This session provides the latest			org/prod/v2/Fron
perspectives	information on treatment options for this type of cancer, including			t/Program/Sessio
	different types of surgery, and radiotherapy.			n?e=377&session
				<u>=14897</u>

		Sunday 4 September					
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
09:30- 11:00	Airway diseases: Precision medicine for asthma, chronic obstructive pulmonary disease and chronic cough: new drugs, biomarkers and approaches	Precision medicine considers individual differences in patients' genes, environments, and lifestyles to allow them to receive personalised treatments. This session will look at the use of precision medicine for asthma, COPD and chronic cough. In particular it will include: • how COPD can be affected by biological changes across a person's lifetime • the link between chronic cough and chronic pain and how this might affect treatments • how biomarkers, such as genes and other biological characteristics, can be used to personalise treatment of lung diseases • a patient describing their experience of having severe asthma and receiving treatment for it • how differences in the way that mucus forms and is cleared by a person's airway can be used to personalise treatments for people with asthma and COPD.	State of the Art	Includes a patient speaker	Asthma Chronic cough COPD	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14205	Yes
09:30- 11:00	Holistic management and rehabilitation of fibrosing interstitial lung diseases	This session will provide updates on the latest non-drug treatments for fibrosing interstitial lung diseases (f-ILDs), such as Idiopathic Pulmonary Fibrosis (IPF). It will include: • the experiences of a patient with IPF who received a lung transplant	Symposium	Includes a patient speaker	Interstitial lung diseases including idiopathic	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session?	Yes





		 how digital health technologies are used to support self-management and rehabilitation for people with f-ILD and how this was influenced by the COVID-19 pandemic how supportive care is provided to people with f-ILD to help manage their physical and psychological symptoms, and how this was affected by the COVID-19 pandemic an update on pulmonary rehabilitation for f-ILD, including the latest research and what adaptations had to be made during the COVID-19 pandemic how oxygen can be used to help with breathlessness in people with f-ILD. 			pulmonary fibrosis	<u>e=377&ses</u> <u>sion=14092</u>	
09:30- 11:00	Moving to prevention of preschool wheeze and asthma: almost there?	 This session will look at wheeze and asthma in children below school age. It will include: a parent of a child with pre-school wheeze talking about the challenges this brings how the lung reacts to infection and inflammation and how this can differ between people what we currently know about wheeze in children below school age and how it can be managed how bacterial lysates (mixtures of inactivated bacteria) could be used to treat asthma and preschool wheeze a summary of recent research into how asthma might be prevented. 	Hot Topic	Includes a patient speaker	Paediatric asthma and wheeze	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14546	Yes
09:30- 11:00	Thoracic oncology: Unravelling lung cancer mazes: a call for an aggressive approach	This session will outline new developments in the treatment of lung cancer. It will include the following topics: • the experience of a patient who was diagnosed with stage 4 lung cancer and took part in a clinical trial	State of the Art	Includes a patient speaker	Lung cancer	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14311	Yes





		 whether surgery should be considered for oligometastatic disease – a type of non-small cell lung cancer that has spread to other parts of the body the latest developments in targeted therapy for non-small cell lung cancer how immunotherapy treatment is used in early non-small cell lung cancer the latest developments in the treatment of breathlessness in patients with lung cancer. 				
09:45- 11:00	Update on nontuberculous mycobacterial pulmonary diseases	This session will look at recent research and guidance into the treatment and management of nontuberculous mycobacterial (NTM) pulmonary diseases. It will include: • how to treat an infection with less common types of NTM bacteria • how underlying health problems might make it more likely for someone to develop NTM lung disease • the latest information on treatments for NTM lung disease.	Mini symposium	Nontuberc ulous mycobacter ial pulmonary diseases (NTM-PD)	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14568	No
10:00- 10:30	Idiopathic pulmonary fibrosis: an update of diagnosis and treatment recommendations	This session will provide a summary of the updated guidelines for diagnosing and treating idiopathic pulmonary fibrosis (IPF).	Guidelines session	Idiopathic pulmonary fibrosis	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14486	No
11:15- 12:45	The best of the European Respiratory Journal in 2022	This session will present a summary of the best research from the European Respiratory Journal in 2022 in three key areas: • interstitial lung disease • COVID-19, and	Journal session	COVID-19 Interstitial lung disease	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session?	Yes





		 respiratory epidemiology – the study of the frequency and pattern, and causes and risk factors, of illness and other factors relating to health. The session will then summarise the research highlights in topics not covered by the first three talks. 		Othe disea	r lung <u>e=377&se</u> se <u>sion=1419</u>	
14:15- 15:45	What I learnt from COVID-19 to better manage my current patients	This session will discuss what health professionals learned from the COVID-19 pandemic and how this can be used to improve the care of lung conditions. This will include: • how the pandemic changed the way that health professionals treat severe acute respiratory failure • how the increase in the use of digital health in the pandemic will change the care of patients with obstructive lung disease • the World Health Organization's views about making pulmonary rehabilitation more accessible • how the care of children with chronic respiratory disease has changed during the pandemic and what could be improved in the future.	Symposium	lung disea Paed chror lung disea Pulm rehab	ructive ersnet.org prod/v2/F prod/v2/F ont/Progra iatric m/Session e=377&se sion=1419 ase onary bilitati re erratory	Z C 2 2 ?
15:45- 17:00	Tobacco control	This session will look at the changes and developments that took place during the pandemic in the areas of tobacco, nicotine alternatives and	Mini	Nicot and	tine <u>https://k4</u> ersnet.org	
17.00	during the pandemic	 other inhaled substances. The presentations will cover: the health effects of menthol, aromas and tobacco free nicotine alternatives, and the law regulating these products how tobacco companies have been investing in the pharmaceutical industry and what can be done about this what can be done to prevent children being exposed to tobacco advertising. 	symposium	tobac		<u>r</u> <u>a</u> ?





16:00-	The future of	Inhalation therapy is the delivery of medications directly into the lungs by	Hot Topics		COPD	https://k4.	Yes
17:30	inhalation therapy in	inhaling, usually through a device such as an inhaler. This session will	110t Topics		6012	ersnet.org/	163
	COPD	discuss the latest developments in this treatment for COPD.				prod/v2/Fr	
		It will include:				ont/Progra	
		 new bronchodilator medications – these treatments help widen 				m/Session?	
		the airways				<u>e=377&ses</u>	
		 new treatments that target inflammation in the lungs 				<u>sion=14544</u>	
		 new medications to both prevent and treat microbial infections 					
		in the lungs					
		the latest devices to deliver inhaled treatments into the lungs.					
16:00-	Update on	This session will provide an update on the treatment of pulmonary	Symposium		Pulmonary	https://k4.	No
17:30	pulmonary embolism	embolism (PE). It will address:	,pee.a		embolism	ersnet.org/	
	management	whether anticoagulation treatment, that aims to stop blood				prod/v2/Fr	
		clotting easily, should be given to people with cancer who have				ont/Progra	
		PE				m/Session?	
		 how to prevent and treat PE linked to a COVID-19 infection 				<u>e=377&ses</u>	
		 whether it is helpful to define a patient as having PE 'provoked' 				sion=14098	
		by a health condition or risk factor or not, to decide what					
		treatment they should be given.					
16:00-	Post-critical care	Long-COVID is a set of symptoms that continue or develop after someone	Symposium	Includes a	COVID-19	https://k4.	Yes
17:30	long COVID: reducing	has had a COVID-19 infection. This session will discuss the care of people		patient		ersnet.org/	
	the physical and	who develop long-COVID after a stay in an intensive care unit (ICU) with		speaker		prod/v2/Fr	
	emotional toll	COVID-19. It will include:				ont/Progra	
		 a patient who spent time in the ICU with COVID-19 talking about 				m/Session?	
		their recovery				<u>e=377&ses</u>	
		 the symptoms and signs of long-COVID after a stay in the ICU and why these might occur 				sion=14099	
		how people receiving mechanical ventilation (using a machine to					
		help with breathing) can be helped to stop using the ventilation,					
		and how physiotherapy might help them recover					





the treatment of anxiety, depression and cognitive impairment
('brain fog')
rehabilitation to help physical symptoms associated with long-
COVID.

		Monday 5 September					
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
09:30- 11:00	Interstitial lung diseases: Trends, controversies and open questions in ILD	 This session will provide an update on interstitial lung diseases (ILDs). It will cover: new ways of diagnosing and treating cystic lung diseases, such as LAM (lymphangioleiomyomatosis) new research into preventing and treating acute exacerbations (a sudden worsening of symptoms) in people with fibrosing ILDs ways to diagnose and treat lung problems in people with autoimmune diseases such as rheumatoid arthritis, vasculitis and connective tissue disorders the potential harmful effect on the lungs of certain treatments and medical devices. 	Symposium		Interstitial lung diseases including LAM	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14199	Yes
09:30- 11:00	Treatment of acute respiratory failure in chronic obstructive pulmonary disease patients	 This session will provide an update on new and existing treatments for acute respiratory failure in people who have COPD. It will discuss: whether non-invasive ventilation and nasal high-flow therapy are helpful for acute respiratory failure in COPD whether invasive ventilation might be helpful, including an outline of new technologies in this area the long term outcomes after a COPD exacerbation (worsening of symptoms), including the effect on quality of life, how recovery is monitored, and what treatments might help improve outcomes. 	Symposium		Acute respiratory failure in COPD	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14094	Yes





09:30-	Bronchiectasis: how	This session will discuss recent developments in personalised medicine	Hot Topics	Dr	ronchiect	https://k4.	Yes
11:00	recent advances in	for bronchiectasis. It will include:	Tiot Topics		sis	ersnet.org/	163
11.00	research can support	how analysing a person's microbiome can help understand and		as	313	prod/v2/Fr	
	personalised	treat bronchiectasis. The microbiome is the collection of				ont/Progra	
	medicine in practice	microbes, such as bacteria and fungi, that live in or on the human				m/Session?	
	medicine in practice	body.				e=377&ses	
		 whether looking at the inflammation in a person's airway can 				sion=14566	
		help decide on treatment for bronchiectasis				31011-1-300	
		 how technology can help diagnose and treat bronchiectasis 					
		which health professionals should work together in a					
		multidisciplinary team to assess and manage bronchiectasis.					
		, , , , , , , , , , , , , , , , , , ,					
09:30-	Dangers in the air we	This session will describe new findings about air pollution. It will cover:	Symposium	Ai	ir	https://k4.	Yes
11:00	breathe	 how elements in the environment, such as pollution and 		рс	ollution	ersnet.org/	
		allergens, can contribute towards allergic respiratory diseases				prod/v2/Fr	
		such as asthma and rhinitis				ont/Progra	
		 how climate change, and associated factors such as smoke, smog 				m/Session?	
		and airborne allergens, can affect the lung health of children and				<u>e=377&ses</u>	
		adults				sion=14100	
		 the possible health effects of microplastics and microfibres in 					
		the air					
		 how inhaling diesel particles from vehicle exhausts can 					
		contribute to inflammation of the lungs.					
09:45-	The two sides of	This session uses findings from scientific research to try to explain why	Mini	Ol	bstructive	https://k4.	No
11:00	every story: New	people with obstructive sleep apnoea (OSA) may have different	symposium	sle	leep	ersnet.org/	
	translational insights	symptoms from each other and respond to treatment differently.		ар	pnoea	prod/v2/Fr	
	into the	It includes:				ont/Progra	
	heterogeneity of the	 how a person's genes might affect their OSA symptoms and how 				m/Session?	
	obstructive sleep	they respond to treatment				<u>e=377&ses</u>	
	apnea effect and its					sion=14553	
	treatment						





		 how having OSA might both lead to or prevent someone getting myocardial ischaemia, which is a condition caused by lack of blood to the heart muscle the possible links between OSA and cancer. 					
11:15- 12:45	How a crisis impacts health care providers and patients	 This session examines how a health crisis such as the war in Ukraine can have an impact on patients and healthcare professionals. It also considers how international organisations can help. The session includes: the role of the World Health Organization (WHO) when there is a health crisis the story of how a respiratory doctor in Ukraine coped with the outbreak of war the experiences of a patient with a lung condition in Ukraine when war broke out how war can affect how healthcare is organised how to provide care for refugees how the ERS can support respiratory healthcare teams during a crisis. 	Symposium	Includes a patient speaker	General healthcare	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=15011	Yes
11:15- 12:45	The Human Lung Cell Atlas: a universal reference for all respiratory scientists	The Human Lung Cell Atlas is a project to describe all the cells in the human lung and nose. It has been created by a group called discovAIR. This session will: • introduce the discovAIR project • explain how the Human Lung Cell Atlas can be used in research • detail some of the groundbreaking methods that were used to produce the atlas.	Hot Topics	Patients were part of the discovAIR project.	Research	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14542	Yes
14:15- 15:45	Pulmonary vascular diseases	This session will provide an update on the understanding and treatment of pulmonary hypertension (PH) caused by an underlying lung disease.	State of the Art		Pulmonary hypertensi on	https://k4. ersnet.org/ prod/v2/Fr	Yes





		 It will cover: how PH can develop in someone with a lung disease, and the impact it can have how autoimmune diseases can lead to PH, and how it can be treated an outline of the results of clinical trials for PH and a look at future trials the diagnosis of pulmonary arterial hypertension in patients with a low DLCO measurement. DLCO (Diffusing Capacity of Lung for Carbon Monoxide) is a measure of how well gases are transferred in the lung. 				ont/Progra m/Session? e=377&ses sion=14200	
14:15- 15:45	Utilising exercise testing in pre-operative assessment, rehabilitation and exercise prescription	This session will provide an overview of the use of exercise in treating and managing lung disease. This will include: • a patient with COPD describing the benefits of taking part in a pulmonary rehabilitation programme • the most common ways to assess exercise capacity, rehabilitation, response to exercise, and fitness for surgery • how exercise testing can be used to assess the risks of surgery and help decide on treatment for patients after surgery • how exercise and increased activity can improve health and disease • how health professionals can prescribe exercise to patients.	Symposium	Includes a patient speaker	Physical activity	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14103	Yes
16:00- 17:30	Update on the diagnosis and treatment of pulmonary hypertension	 This session will provide an update on the new guidelines for diagnosing and treating pulmonary hypertension (PH). It will include: the experiences of a patient who was part of the Task Force producing the new guidelines the most important changes in the new guidelines the new recommendations for treating PH the strengths and weaknesses of the new guidelines 	Symposium	Includes a patient speaker. Patients were involved in the Task Force	Pulmonary hypertensi on	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14309	Yes





		an interactive session discussing clinical cases of PH.		producing the guidelines			
16:00- 17:30	Lung involvement in common variable immunodeficiency: from diagnosis to lung transplantation	This session will provide an overview of common variable immunodeficiency (CVID) and how it is diagnosed and treated. It will cover: • the causes of CVID and how it is diagnosed in children and adults • how to prevent and treat infections in patients with CVID • what complications other than infections can occur in people with CVID and how they should be treated • lung transplants for patients with CVID, including which patients are not suitable for a transplant, and how patients should be treated after a transplant.	Symposium		Common variable immunodef iciency	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14102	Yes
16:00- 17:30	Pharmacotherapy for sleep disordered breathing	 This session will discuss different drug treatments for sleep disordered breathing (SDB). It will include: drug treatments to help weight loss and how this can help people with SDB how problems with the muscles in the upper airway can lead to SDB, and how medication can help how problems in the way that the brain regulates breathing can lead to SDB, how this can be diagnosed, and how drug treatment can help how medication can help a low arousal threshold. A low arousal threshold happens when a person wakes up easily when they stop breathing in their sleep due to having obstructive sleep apnoea (OSA). It causes disrupted sleep. 	Hot Topics		Sleep and breathing	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14543	Yes
16:15- 16.45	ERS Guideline on various aspects of quality in lung cancer care	This session will outline the new guidelines for providing quality care to people with lung cancer.	Guidelines session	Patients were involved in the	Lung cancer	https://k4. ersnet.org/ prod/v2/Fr ont/Progra	No





		production	m/Session?
		of the	<u>e=377&ses</u>
		guidelines	sion=14524

		Tuesday 6 September					
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
09:00- 11:30	Sleep and breathing disorders: Myth or reality: is obstructive sleep apnoea really critical for cardiovascular complications? Current evidence about pathophysiology, clinical implications and future perspectives	 This session will summarise knowledge about the link between obstructive sleep apnoea (OSA) and problems with the cardiovascular system (the heart and blood vessels). It will include: an explanation of the hypoxic burden, its importance for assessing the severity of OSA, its link with the cardiovascular system, and how it can help to decide on treatment for OSA. The 'hypoxic burden' is a measurement that can be taken during sleep to diagnose sleep disordered breathing (SDB). what endpoints are used in trials looking at OSA and cardiovascular problems. An endpoint is an outcome related to health and disease that is measured in a clinical trial – for example breathlessness or reduction of pain. This talk will also discuss whether the endpoints commonly used reflect patient priorities. It will also consider the use of patient-reported outcome measures (PROMS) in clinical trials. a discussion of the endpoints used to measure the effects of positive airway pressure (PAP) treatment on cardiovascular health a debate on the potential new research methods that are needed in studies of SBD. 	State of the Art		Sleep and breathing	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14204	Yes
09:00- 11:30	Asthma diagnosis: new and old approaches to	This session will provide an update on how asthma is diagnosed in primary care (healthcare provided by a medical professional, such as a GP, with whom a patient has initial contact).	Primary care session		Asthma	https://k4. ersnet.org/ prod/v2/Fr	Yes





	increase primary care capability	 It will include: how asthma is diagnosed in primary care and how this can be improved how peak flow and FeNO (fractional exhaled nitric oxide) tests are used to diagnose asthma the use of oscillometry to diagnose and monitor asthma how written action plans can help patients to recognise asthma symptoms and improve their condition. 			ont/Progra m/Session? e=377&ses sion=14194	
09:45- 11:00	State-of-the-art in the home mechanical ventilation	 This session will outline new developments in home mechanical ventilation (HMV), where a machine is used to help with breathing. It will cover: developments in the diagnosis and treatment of chronic respiratory failure in people with neuromuscular disorders (NMD), such as motor neurone disease (MND), including how HMV can help new techniques to clear lung secretions and improve the effectiveness of cough in people with NMDs new developments in the care of people receiving HMV. This includes care at home, how patients are followed up, and how health professionals assess the effectiveness of treatments. 	Mini symposium	Home mechanical ventilation Neuromusc ular disease	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14554	No
11:15- 12:45	The many faces of central sleep apnoea and hypoventilation syndromes	This session will look at the different types of central sleep apnoea and hypoventilation syndrome. It will include: • how there are different types of central sleep apnoea, and whether they should be treated • an explanation of sleep apnoea caused by opioid medications • new research into obesity hypoventilation syndrome, including how it can be treated	Symposium	Sleep and breathing	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14091	Yes





		 the advantages and disadvantages of using positive airway pressure (PAP) and non-invasive ventilation (NIV) devices to treat hypoventilation syndromes in adults and children. 					
11:15- 12:45	Paediatric respiratory diseases	 This session will look at different aspects of lung disease in children. It will include: a parent of a child with sleep apnoea describing their experience of diagnosis and treatment how to diagnose and treat lung infections in children with neurodevelopmental impairment, for example communication disorders and Autism spectrum disorder (ASD) the findings from a recent Task Force looking at paediatric long-term non-invasive ventilation (NIV) recent research on paediatric bronchoscopy, which is a technique used to diagnose lung diseases in children how to assess lung function in children who are being treated in intensive care units (ICU). 	State of the Art	Includes a patient speaker	Paediatric lung disease	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14202	Yes
11:15- 12:45	Forgotten issues in chronic obstructive pulmonary disease: a primary care perspective	 This session will consider different ways to diagnose COPD with alternatives to drug treatments. The session will cover: the connection between COPD and mental health problems and how these can be treated how home-based pulmonary rehabilitation could be used to help people with COPD in low and middle-income countries how healthcare professionals can address sexual health issues in people with COPD how early access to palliative/supportive care can help people with COPD, and a discussion of new treatments for breathlessness in people with severe COPD. 	Primary care session		COPD	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14195	Yes





11:15-	Management of	This session will outline the treatment and management of complicated	Symposium	Includes a	Sarcoidosis	https://k4.	Yes
12:45	complicated	sarcoidosis. It will also discuss the health complications associated with	Symposium	patient	Saicoluosis	ersnet.org/	163
12.43	sarcoidosis	this condition and how they can be treated. It will include:		speaker		prod/v2/Fr	
	Sarcoldosis	•		speaker			
		a patient describing how they manage their complicated				ont/Progra	
		sarcoidosis				m/Session?	
		how fibrotic sarcoidosis can be treated, including a discussion of				<u>e=377&ses</u> sion=14105	
		new treatments available				51011-14105	
		an explanation of sarcoidosis-associated pulmonary					
		hypertension, and how it is diagnosed and treated					
		infections associated with sarcoidosis, such as aspergillus, and					
		how they can be treated and managed					
		the latest recommendations for diagnosing and treating complex					
		extrapulmonary sarcoidosis. This is sarcoidosis occurring in					
		organs outside the lungs, such as the heart and brain.					
44.45	FDC II : I		6 : 1 !:	5		1/1 4	
11:15-	ERS clinical practice	This session will outline the new guidelines for how healthcare	Guidelines	Patients	Asthma	https://k4.	No
11:45	guidelines for the	professionals should diagnose asthma in adults.	session	were		ersnet.org/	
	diagnosis of asthma			involved in		prod/v2/Fr	
	in adults			the		ont/Progra	
				production		m/Session?	
				of the		<u>e=377&ses</u>	
4445	A C I			guidelines		sion=14523	,,
14:15-	Artificial	This session will look at how artificial intelligence (AI) is used in	Hot Topics		Lung	https://k4.	Yes
15:45	intelligence applicati	diagnosing and treating lung cancer. It will include the use of AI in:			cancer	ersnet.org/	
	ons in thoracic	lung cancer screening				prod/v2/Fr	
	oncology: an	lung cancer diagnosis				ont/Progra	
	overarching	 diagnosis of plural malignancies. These are cancers that develop 				m/Session?	
	ambition or	in the pleura, the thin layer of tissue that surrounds the lungs.				<u>e=377&ses</u>	
	overarching benefit?	 deciding on how to treat people receiving systemic therapy for 				<u>sion=14547</u>	
		lung cancer, such as chemotherapy and immunotherapy.					
1							





14:15- 15:45	Occupational COVID- 19: current and future impact	 This session will discuss issues related to people who developed COVID-19 because of their job, for example healthcare workers. It will include: the results of a study looking at the risk factors associated with getting COVID-19 at work, and which professions were most affected an overview of long-COVID, including its frequency and symptoms. The speaker is a lung specialist who also has long-COVID, so they will also talk about their personal experience. how vaccines are developed, how this was speeded up during the COVID-19 pandemic, and what can be learned for future pandemics the results of an international ELF survey looking at people's concerns about COVID-19 in the workplace and returning to work after the pandemic. 	Hot topics	Includes a patient speaker, and the results of ELF's COVID-19 and the workplace survey	COVID-19	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14545	Yes
14:15- 15:30	Long-term impact of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis patients and potential changes in the management of the disease in CF units	Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a new drug treatment for cystic fibrosis (CF). This session will look at: • how these new drugs will change the treatment and management of CF and the other health conditions associated with it • the use of CFTR modulators in children • research into why some people with CF don't respond to treatment with CFTR modulators.	Mini symposium		Cystic fibrosis	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14552	No
16:00- 17:30	Towards elimination of COPD	This session will look at COPD, its frequency, how it can be treated, and what could be done to try to eradicate it. It will cover: • how COPD has come to be the third most common cause of death worldwide, and what patients expect from governing authorities, healthcare professionals and treatments	Hot Topics		COPD	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session?	Yes





		 new concepts for diagnosing and treating COPD what new drug and non-drug treatments are needed for COPD what needs to happen to reduce the number of people worldwide with COPD. 			<u>e=377&ses</u> <u>sion=14573</u>	
16:00- 17:30	The practice and the planet: how can climate change and air pollution be addressed from clinical practice?	 This session will discuss the latest research on the effect of climate change and air pollution on lung health, and what health professionals can do to help lessen the impact. It will include: the links between health professionals and climate change, and how they can support action to reduce it how topics linked to the health of the planet can be introduced into medical training a look at the new World Health Organization Air Quality Guidelines and what they mean for health professionals and patients, and a discussion of the impact of air pollution on lung health the latest research on the link between low levels of air pollution and lung disease in children. 	Hot Topics	Air pollution	https://k4. ersnet.org/ prod/v2/Fr ont/Progra m/Session? e=377&ses sion=14627	Yes



